Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

January 29, 2024

https://www.globenewswire.com/news-release/2024/01/29/2819452/0/en/Cidara-Therapeutics-Announces-Approval-of-REZZAYO-by-the-MHRA-for-the-Treatment-of-Invasive-Candidiasis-in-Adults.html

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults.

Read more at globenewswire.com

Related news for (CDTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.